Vietnam Country Case Study ASEAN Vaccine Development and Manufacturing Research Project

This regional analytical activity will contribute to knowledge on the technical, operational, and financial viability and strategic partnership required among ASEAN countries to strengthen coordinated investments on the vaccine value chain. The ASA has three major activities: i) A deep-dive public s...

Full description

Bibliographic Details
Corporate Author: World Bank Group
Format: eBook
Language:English
Published: Washington, D.C The World Bank 2023
Series:Other Health Study
Subjects:
Online Access:
Collection: World Bank E-Library Archive - Collection details see MPG.ReNa
LEADER 01657nmm a2200277 u 4500
001 EB002177140
003 EBX01000000000000001314674
005 00000000000000.0
007 cr|||||||||||||||||||||
008 231006 ||| eng
245 0 0 |a Vietnam Country Case Study  |h Elektronische Ressource  |b ASEAN Vaccine Development and Manufacturing Research Project 
260 |a Washington, D.C  |b The World Bank  |c 2023 
653 |a Investments 
653 |a Vaccine Security 
653 |a Health, Nutrition and Population 
653 |a Financial Viability 
653 |a Value Chain 
653 |a Immunizations 
710 2 |a World Bank Group 
041 0 7 |a eng  |2 ISO 639-2 
989 |b WOBA  |a World Bank E-Library Archive 
490 0 |a Other Health Study 
028 5 0 |a 10.1596/40001 
856 4 0 |u http://elibrary.worldbank.org/doi/book/10.1596/40001  |x Verlag  |3 Volltext 
082 0 |a 330 
520 |a This regional analytical activity will contribute to knowledge on the technical, operational, and financial viability and strategic partnership required among ASEAN countries to strengthen coordinated investments on the vaccine value chain. The ASA has three major activities: i) A deep-dive public sector technical assessment of country and regional level vaccine security, including gaps and opportunities across the value chain from RandD to last mile distribution; ii) A private sector value chain analysis covering upstream and downstream aspects of vaccine manufacturing; and iii) An economic analysis examining the feasibility of coordinated investments across countries to leverage comparative advantage in specific aspects of the vaccine value chain